Zepbound, Birth Control, and Pregnancy: What the Label Says

If you take Zepbound (tirzepatide) and use birth control pills, there is one piece of guidance you cannot afford to skim: tirzepatide can make oral contraceptives less effective, and the FDA-approved label tells you specifically what to do about it. This is not a vague theoretical concern or an online rumor — it is a direct, label-mandated warning. This page lays out exactly what the prescribing information says, why it happens, and the pregnancy guidance that goes with it. Because this is a high-stakes topic, we quote the label rather than paraphrase loosely.

The core warning: oral birth control can fail on Zepbound

Zepbound's FDA prescribing information states plainly that the drug can reduce the absorption of oral hormonal contraceptives, and it gives a concrete instruction. Patients using birth control pills should either switch to a non-oral contraceptive method, or add a barrier method of contraception (such as condoms), for 4 weeks after starting Zepbound and for 4 weeks after each dose increase¹. This same guidance appears in multiple sections of the label — the Highlights, the Drug Interactions section, and the contraception guidance — which signals how seriously the manufacturer and FDA treat it¹.

The two windows that matter most are therefore: the first month on the drug, and the first month after every dose escalation (Zepbound is titrated upward in steps). During those windows, the pill alone should not be relied on.

How big is the effect on absorption? The label reports the actual numbers from a drug-interaction study in which a combined oral contraceptive was given with a single 5 mg dose of tirzepatide. The peak concentration (Cmax) of the contraceptive hormones fell substantially — ethinyl estradiol by 59%, norgestimate by 66%, and norelgestromin by 55% — while total exposure (AUC) fell by about 20–23%, and the time to peak was delayed¹. In plain terms: less hormone reaches the bloodstream, and it arrives later. That is enough to put contraceptive reliability in question during the high-risk windows, which is why the label calls for a backup or non-oral method rather than treating it as minor.

Why it happens: delayed gastric emptying

The mechanism is the same one behind tirzepatide's appetite and nausea effects. Tirzepatide slows gastric emptying — it makes the stomach release its contents into the intestine more slowly². A pharmacology study confirmed tirzepatide transiently delays gastric emptying, much like long-acting GLP-1 receptor agonists, and that this effect is greatest at the start of treatment and after dose increases, then attenuates over time². Because an oral pill has to dissolve and be absorbed from the gut, slowing and disrupting that transit blunts and delays how much hormone gets in³. That timing — strongest early and after each step up — is exactly why the label's 4-week backup windows are placed where they are.

Importantly, this is a problem of the oral route, not the hormones themselves. Non-oral contraceptives — an IUD (hormonal or copper), the implant, the injection, the patch, or the vaginal ring — bypass the gut entirely, so they are not subject to this absorption issue. That is why "switch to a non-oral method" is the cleaner of the label's two options for many people.

Pregnancy: Zepbound is not for use in pregnancy

The contraception warning exists because of a second, equally important message in the label: Zepbound should not be used during pregnancy. The prescribing information states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and it instructs that Zepbound be discontinued when pregnancy is recognized¹. Animal reproduction studies showed adverse developmental effects, and there are no adequate data establishing safety in human pregnancy¹.

There is a practical wrinkle worth knowing. Because effective weight loss can restore ovulation and fertility in people who weren't ovulating regularly, some people become more fertile on these drugs than they expect — the so-called "Ozempic baby" phenomenon discussed for the GLP-1 class. That makes reliable contraception more important on Zepbound, not less, for anyone who could become pregnant and isn't trying to. If you are planning a pregnancy, this is a conversation to have with your clinician about when to stop the drug beforehand; see our guide on stopping tirzepatide.

What to actually do

The label's instructions translate into a short, concrete checklist:

• •If you use the pill (or patch/ring taken to be safe), add a barrier method or switch to a non-oral method for 4 weeks after you start Zepbound and for 4 weeks after every dose increase¹.
• •Consider a non-oral method outright — IUD, implant, injection — which sidesteps the absorption problem entirely and removes the need to track backup windows.
• •Don't use Zepbound if you are pregnant or trying to conceive, and stop it if you discover you're pregnant, then tell your clinician¹.
• •Talk to your prescriber about timing if you're planning a pregnancy, given tirzepatide's dosing schedule and the restored-fertility effect.

For the wider GI effects that share this delayed-emptying mechanism, see Zepbound side effects; for how the dose steps that trigger each new backup window are structured, see the tirzepatide dosage chart.

The honest bottom line

This is one of the few Zepbound interactions where the guidance is not a judgment call — it's written into the FDA label. Tirzepatide measurably reduces the absorption of oral contraceptive hormones (peak levels cut by more than half in a label study), because it slows gastric emptying most at the start and after dose increases¹². The label's answer is unambiguous: use a non-oral method, or add a barrier method, for 4 weeks after starting and 4 weeks after each dose escalation¹. And because Zepbound can cause fetal harm and may restore fertility, it should be stopped in pregnancy and discontinued when pregnancy is recognized¹. When the stakes are an unplanned pregnancy, follow the label exactly and confirm your plan with your prescriber. For the full evidence picture, start with our tirzepatide evidence guide, and to compare providers, see best tirzepatide.